EyePoint's DURAVYU misses Phase 3 LUCIA primary endpoint; 53% workforce cut, wet AMD trials halted

EyePoint, Inc.

• Phase 3 LUCIA study of DURAVYU in wet AMD did not meet the primary endpoint of non-inferiority, though vision improved and key secondary endpoints were met.
• EyePoint will conclude both pivotal Phase 3 wet AMD trials early, without completing year two, and cut approximately 53% of positions, mostly in Q4 2026, finishing in 1H 2027.
• Restructuring carries about $9M in severance and related charges but is expected to generate roughly $30M in annualized savings.
• Company estimates ~$118M in cash, cash equivalents and short-term investments as of September 30, 2026; figures are preliminary and unaudited.
• Resources now focus on DURAVYU in DME, with Phase 3 COMO and CAPRI (551 patients) topline data expected in Q4 2027; VERONA Phase 2 showed >70% supplement-free at six months.